CAS 1095004-78-6

Fórmula: C27H30FN5O3

InChI: InChI=1S/C27H30FN5O3/c1-17-21(28)15-18(25(34)31-19-7-8-19)16-22(17)33-13-11-30-24(26(33)35)32-27(9-10-27)20-5-3-4-6-23(20)36-14-12-29-2/h3-6,11,13,15-16,19,29H,7-10,12,14H2,1-2H3,(H,30,32)(H,31,34)

Clave InChI: NNKPHNTWNILINE-UHFFFAOYSA-N

SMILES: CC1=C(C=C(C=C1F)C(=O)NC2CC2)N3C=CN=C(C3=O)NC4(CC4)C5=CC=CC=C5OCCNC

AZD7624

CAS: 1095004-78-6

AZD7624 is an p38 inhibitor. It has potent anti-inflammatory activity.

Fórmula: C₂₇H₃₀FN₅O₃

Pureza: 98.82%

Forma y color: White Solid

Peso molecular: 491.5572

Ref: TM-T14381

AZD7624

CAS: 1095004-78-6

AZD7624

Fórmula: C₂₇H₃₀FN₅O₃

Pureza: ≥98%

Peso molecular: 491.56

Ref: 54-BUP04820

N-Cyclopropyl-3-fluoro-4-methyl-5-(3-((1-(2-(2-(methylamino)ethoxy)phenyl)cyclopropyl)amino)-2-oxopyrazin-1(2H)-yl)benzamide

CAS: 1095004-78-6

Fórmula: C₂₇H₃₀FN₅O₃

Peso molecular: 491.5572

Ref: IN-DA01FTTI

AZD7624

CAS: 1095004-78-6

AZD7624 is an inhaled anti-inflammatory compound, which is derived from AstraZeneca's research efforts. It functions as a p38 MAP kinase inhibitor, targeting specific pathways involved in inflammatory responses within the respiratory system. AZD7624 is designed for the modulation of inflammatory processes in diseases such as chronic obstructive pulmonary disease (COPD) and asthma. By inhibiting the p38 MAP kinase, AZD7624 attenuates the production of pro-inflammatory cytokines and other mediators that contribute to the pathological progression of respiratory disorders. Its use is particularly significant in patients suffering from persistent inflammation where traditional therapies may be insufficient. The development of AZD7624 highlights the ongoing efforts to manage inflammatory diseases at the molecular level with a targeted therapeutic approach, providing insights into novel intervention strategies for respiratory illnesses.

Fórmula: C₂₇H₃₀FN₅O₃

Pureza: Min. 95%

Peso molecular: 491.56 g/mol

Ref: 3D-VTB00478